Gilead to Get Attorney Fees in Hepatitis C Patent Fight With Merck

Gilead Sciences Inc. is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc., a U.S. district judge has ruled, **reports Reuters**.

“In June, Gilead was freed from paying up $200 million in damages for infringing two Merck patents related to Gilead’s blockbuster drugs Sovaldi and Harvoni, after a U.S. judge found a pattern of misconduct by Merck including lying under oath and other unethical practices,” writes **Anya George Tharakan**.

The court found that Giliead could receive relief from the cost of its legal fees in defending against the Merck challenge.

Read the story.